.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,037,353

« Back to Dashboard
Patent 6,037,353 protects CHILDREN'S ALLEGRA ALLERGY, CHILDREN'S ALLEGRA HIVES, ALLEGRA, ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION, ALLEGRA ALLERGY, ALLEGRA HIVES, and ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION, and is included in seven NDAs. There has been one Paragraph IV challenge on Allegra. There are five tentative approvals for the compound protected by this patent. Additional details are available via the generic ingredient links below.

Protection for ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has sixteen patent family members in fourteen countries.

Summary for Patent: 6,037,353

Title: Method of providing an antihistaminic effect in a hepatically impaired patient
Abstract:The present invention relates to a method of providing an antihistaminic effect in a hepatically impaired patient in need thereof comprising administering to said patient an effective antihistaminic amount of a compound of the formula ##STR1## wherein R.sub.1 is hydrogen or hydroxy; R.sub.2 is hydrogen; or R.sub.1 and R.sub.2 taken together form a second bond between the carbon atoms bearing R.sub.1 and R.sub.2 ; n is an integer of from 1 to 5; R.sub.3 is --COOH or --COOalkyl wherein the alkyl moiety has from 1 to 6 carbon atoms and is straight or branched; each of A and B is hydrogen or hydroxy with the proviso that at least one of A or B is hydrogen; or a pharmaceutically acceptable salt and individual isomers thereof.
Inventor(s): Woodward; James K. (Cincinnati, OH), Okerholm; Richard A. (West Chester, OH), Eller; Mark G. (Overland Park, KS), McNutt; Bruce E. (Olathe, KS)
Assignee: Hoechst Marion Roussel, Inc. (Bridgewater, NJ)
Application Number:08/397,542
Patent Claim Types:
see list of patent claims
Use;

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Sanofi Aventis Us
CHILDREN'S ALLEGRA ALLERGY
fexofenadine hydrochloride
TABLET, ORALLY DISINTEGRATING;ORAL021909-002Jan 24, 2011OTCYes6,037,353► subscribe RELIEF OF SYMPTOMS ASSOCIATED WITH RESPIRATORY ALLERGIES AND FOR THE RELIEF OF SYMPTOMS ASSOCIATED WITH HIVES (URTICARIA) IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER
Sanofi Aventis Us
CHILDREN'S ALLEGRA ALLERGY
fexofenadine hydrochloride
TABLET, ORALLY DISINTEGRATING;ORAL021909-002Jan 24, 2011OTCYes6,037,353► subscribe RELIEF OF SYMPTOMS ASSOCIATED WITH RESPIRATORY ALLERGIES ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER
Sanofi Aventis Us
CHILDREN'S ALLEGRA HIVES
fexofenadine hydrochloride
TABLET, ORALLY DISINTEGRATING;ORAL021909-003Jan 24, 2011OTCYes6,037,353► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 6,037,353

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,399,632 Method of providing an antihistaminic effect in a hepatically impaired patient► subscribe
6,187,791 Method of providing an antihistaminic effect in a hepatically impaired patient► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 6,037,353

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria194913► subscribe
Australia3973493► subscribe
Australia679910► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc